NRAS and cancer: A completely different explanation may rely on the different immunogenicity of mutated B-RAF and N-RAS or the respective induced effector molecules, as it has been recently suggested for the seemingly paradoxical association of a bcl-2 over-expression with an improved prognosis in cancer patients [21].